The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) has been proposed to standardize salivary gland fine-needle aspiration (FNA) diagnoses. This study assessed salivary gland FNA results and risk of malignancy (ROM) rates at the University of North Carolina as well as the interobserver reliability (IOR) of the atypia of undetermined significance (AUS) and salivary gland neoplasm of uncertain malignant potential (SUMP) categories. METHODS: The electronic medical record was searched for FNA cases from 2010 to 2017 with subsequent surgical resections. Histologic diagnosis was used for gold-standard comparison. The original cytologic results were then converted into MSRSGC categories (nondiagnostic, nonneoplastic, AUS, benign neoplasm, SUMP, suspicious, and malignant). For the assessment of IOR, 23 cases were selected with enrichment for cases diagnosed as AUS (n 5 11) or SUMP (n 5 9). Six boarded cytopathologists and 1 cytopathology fellow assessed representative slides and provided an MSRSGC diagnosis for each case. Fleiss' j coefficients were calculated to determine IOR. RESULTS: The ROM was 33% for both AUS and SUMP cases; however, the risk of neoplasia was 56% for AUS cases and 100% for SUMP cases. Fleiss' j for the AUS category was 0.217 (P < .05), and Fleiss' j for the SUMP category was 0.024 (P 5 .74). CONCLUSIONS: In this study assessing the IOR of MSRSGC categories, fair agreement and slight agreement were found for the AUS and SUMP categories, respectively. Observers preferentially used the AUS or benign neoplasm category for SUMP cases, perhaps because of unfamiliarity with SUMP as a diagnostic option. The initial adoption of a new reporting system will require a quality assessment to ensure that the system is reliable and useful for clinicians. Cancer Cytopathol 2018;126:390-6.
INTRODUCTION
The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) has recently been proposed as a means of standardizing salivary gland fine-needle aspiration (FNA) diagnoses. The use of FNA to evaluate salivary gland lesions is well established and has value in guiding the management of superficial masses. FNA is widely accepted and used because it is cost-effective, is easily performed in an outpatient setting, and can reduce the number of unnecessary surgeries. [1] [2] [3] [4] One of the few criticisms of this technique includes suboptimal diagnostic sensitivity and specificity when benign and malignant entities are being differentiated. In a study of 709 salivary gland FNA cases with surgical follow-up, Rossi et al 5 calculated a sensitivity of 69.1%, a specificity of 97.6%, and a diagnostic accuracy of 91.3%. Atypical and suspicious diagnoses, particularly when those categories are not well defined, often contribute to lower procedural specificity, and this leaves clinicians to interpret and treat on the basis of the specific clinical scenario.
Standardized reporting systems are not a new concept in cytopathology. Ideally, they provide uniform reporting across practice settings and guide treatment decisions on the basis of the risk of malignancy (ROM). Currently, there is no standard reporting system for salivary gland cytology, and this leaves room for descriptive diagnoses and less concrete information for clinicians. The Bethesda System for Reporting Cervical Cytology (TBSRCC) and The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) have been successfully and widely implemented. However, ambiguity still exists within current standardized reporting schemes. Indeterminate categories in TBSRCC are atypical squamous cells of undetermined significance and atypical squamous cells, cannot exclude high grade squamous intraepithelial lesion, whereas the indeterminate categories in TBSRTC include atypia of undetermined significance/follicular lesion of undetermined significance and suspicious for malignancy. Studies have shown that these ambiguous categories have poor interobserver reliability (IOR), especially in cases with limited cellularity or only focal atypia. [6] [7] [8] [9] In addition, TBSRCC and TBSRTC contain well-defined adequacy criteria for the interpretation of direct smears that establish a minimum baseline cellularity for evaluation and are a measure of quality assurance for each procedure.
The MSRSGC is the first step in standardizing salivary gland cytology but contains some indeterminate diagnostic categories, including atypia of undetermined significance (AUS), salivary gland neoplasm of uncertain malignant potential (SUMP), and suspicious for malignancy. The MSRSGC proposes an ROM for each category with the goal of providing clinicians information needed to standardize treatment decisions. In this study, we retrospectively applied MSRSGC diagnostic categories to salivary gland FNA cases at our institution, calculated their associated ROM, and focused on the IOR of the problematic AUS and SUMP categories.
MATERIALS AND METHODS
After institutional review board approval, the laboratory information system at the University of North Carolina Hospitals was searched for all salivary gland FNA cases to include parotid and submandibular gland masses with subsequent histologic resections available from 2010 to 2017. Cases were identified by accession number, and linked cytologic/histologic details were recorded to include the patient age, sex, FNA location, final cytologic and histologic diagnosis, and follow-up management. All FNA cases were reviewed, and cytologic diagnoses were converted into MSRSGC categories (nondiagnostic, nonneoplastic, AUS, benign neoplasm, SUMP, suspicious, and malignant) retrospectively by 1 pathologist (J.M.H.) on the basis of currently available definitions (Table 1) . MSRSGC categories were assigned to cases solely on the basis of the interpretation of the final diagnostic reports. When we were evaluating concordance between FNA diagnoses and surgical resection histologic diagnoses, the histologic diagnoses were interpreted as 1) nonneoplastic, 2) benign neoplasm, or 3) malignant. If the FNA diagnosis in the MSRSGC category could feasibly include the histologic diagnostic category, the 2 results were considered concordant.
Cases that lacked either qualitative or quantitative features to be diagnosed as nonneoplastic or neoplastic were placed into the AUS category. For the AUS and SUMP categories, any diagnostic comments were taken into consideration, and the case was assigned to the category of best fit. For example, if the FNA diagnosis was The aspirate is diagnostic of malignancy.
Abbreviations: AUS, atypia of undetermined significance; MSRSGC, Milan System for Reporting Salivary Gland Cytopathology; SUMP, salivary gland neoplasm of uncertain malignant potential.
AUS, essentially any pathologic diagnosis on surgical resection would be concordant, and for the FNA result of SUMP, any neoplastic or malignant histologic diagnosis would be concordant. Subsequently, these data were used to determine the overall rates of our institution's use of each diagnostic category over the study period, overall risk of neoplasia (RON), ROM, and risk of high-grade malignancy. High-grade malignancies included adenoid cystic carcinoma, oncocytic carcinoma, high-grade mucoepidermoid carcinoma, adenocarcinoma not otherwise specified, and metastatic squamous cell carcinoma. From the cases identified in the original search, 23 FNA cases were selected for use in the IOR study. All cases had both air-dried Diff-Quik-stained and alcohol-fixed Papanicolaou-stained direct smears available for review by the first author (J.M.H.). All FNA slides were conventional smears prepared at the time of the procedure. The 23 cases were enriched with MSRSGC diagnoses of AUS (n 5 11) and SUMP (n 5 9). The remainder of the cases spanned from benign to malignant. Six cytopathologists and 1 cytopathology fellow were asked to perform a blinded review of representative slides (1 Diff-Quik-stained direct smear and 1 Papanicolaou-stained direct smear) for each case and provide an MSRSGC category diagnosis for each case. Participants were provided with minimal clinical history (age, sex, and site of FNA) and the definitions of each MSRSGC category (the same as those in Table 1 ), and they had specific instructions to adhere to the proposed MSRSGC categories. For cases with only a lymphoid population, if flow cytometry analysis should be requested to rule out a neoplastic hematolymphoid process, participants were told to interpret the cases as AUS. In addition, we collected the following data on the cytopathology observers: number of years in practice, percentage of clinical time spent on cytology, and level of familiarity with the proposed MSRSGC (from no familiarity
[0] to very familiar [10] ). Data were tabulated with Excel (Microsoft Systems, Redmond, Washington), and Fleiss' j coefficients were calculated with Real Statistics (Real Statistics Resource Pack software, release 5.1) to assess IOR.
RESULTS
We identified 134 salivary gland FNA cases from our institution spanning the years 2010-2017. Seventy-seven of the cases (57%) had procedural follow-up in the form of repeat FNA, core biopsy, or resection. The age of the patients ranged from 6 to 89 years, and the mean age was 58.3 years. The male-to-female ratio was 1.1:1. The most common FNA site was the parotid gland (n 5 119 [89%]), which was followed by the submandibular gland (n 5 15 [11%]). No FNA cases from minor salivary glands were included in the study.
Of the 77 cases with follow-up, 74 had tissue submitted to surgical pathology (71 excisions and 3 core biopsies), whereas 3 were repeat FNA. Cytologic-histologic concordance was observed in 64 of the 74 total cases (86%) with surgical resection/core biopsy. Of the 74 samples with subsequent biopsy/excision, 8 had initially nondiagnostic FNA diagnoses, and subsequent procedures (1 core biopsy and 7 surgical resections) showed the following: 3 were malignant (squamous cell carcinoma, mucoepidermoid carcinoma, and lymphoma), 3 were benign (all pleomorphic adenomas), and 2 were nonneoplastic (chronic sialadenitis). One of the 2 remaining nonconcordant cases was called a reactive lymph node on FNA and turned out to be a low-grade follicular lymphoma, and the other was initially signed out as reactive changes and chronic inflammation but turned out to be small cell carcinoma.
The overall use of each MSRSGC category at our institution and the associated RONs and ROMs are shown in Table 2 . The combined prevalence of atypical and Original Article SUMP cases was 16%, with the resulting ROM for atypical cases (33%) being equal to that for SUMP cases (33%). The RON was 56% for the AUS category and 100% for the SUMP category. All malignant cases within the AUS category (n 5 3) were diagnosed as lymphoma upon resampling, whereas all malignancies within the SUMP category (n 5 2) were high-grade malignancies. It is worth noting that 6 of the 6 total SUMP cases were neoplastic in our study. Our ROM rates were above the proposed MSRSGC rates in the nondiagnostic (38%) and nonneoplastic categories (17%) and closely approximated the suggested rates for the AUS (33%), benign (4%), SUMP (33%), suspicious (67%), and malignant categories (100%; Table 2 ).
In the IOR portion of the study, the category selected by individual observers matched the assigned MSRSGC case in 17% to 52% of the total cases, whereas their concordance ranged from 18% to 45% (mean, 24%) in the AUS category and from 11% to 78% (mean 33%) in the SUMP category (Table 3) . Fleiss' j for the AUS category was 0.217 (P < .05), and Fleiss' j for the SUMP category was 0.024 (P 5 .74). Cytopathologist survey results of familiarity with the MSRSGC ranged from 1 to 9 (mean, 4.4), and years of practice ranged from 1.5 to 29 (mean, 13.1 years), with the cytopathology fellow excluded. All pathologists who participated in the IOR part of the study had spent at least 15% of their time averaged over the last 3 years signing out cytology (mean, 29.7%). Figure 1 highlights 2 cases included in the IOR study. The case designated AUS was composed of sparsely cellular oncocytic appearing cells in loose clusters (Fig.  1A,B) . The case was originally signed out as atypical cell groups present, cannot exclude a neoplasm. The follow-up biopsy showed a benign parotid gland. The case designated as SUMP contained numerous groups of basaloid cells with high nuclear-to-cytoplasmic ratios, some of which contained peripheral basement membrane material ( Fig.  1(C,D) . No necrosis or overt mitotic activity was identified, and the case was signed out as a basaloid neoplasm. Follow-up surgical resection revealed a basal cell adenoma.
DISCUSSION
The adoption of a new reporting system within pathology can bring many changes to the interpretation and reporting of cases at a single institution. Upon adopting TBSRTC, Theoharis et al 10 analyzed thyroid FNA reports before and after adoption and scrutinized reporting differences and diagnostic parameters. They saw a decrease in the rate of nondiagnostic cases and the use of "non-committal descriptive diagnoses" in addition to a slight increase in diagnostic accuracy. Another study by Grapsa and Politi 11 looked at more general ramifications of standardized reporting systems in cytology. They noted that without standardization, particularly in difficult cases, descriptive diagnoses can lead to the overuse of atypical or suspicious as a modifier. They can even lead to long descriptive diagnoses that clinicians may choose to interpret in ways that best fit their clinical impression and may be incoherent to other cytopathologists. Standardized reporting systems are praised for their brevity and ability to clearly communicate cytologic data into useful clinical information. Abbreviations: AUS, atypia of undetermined significance; SUMP, salivary gland neoplasm of uncertain malignant potential.
Institutional Use of MSRSGC Categories and ROM
most categories but were slightly higher in the nonneoplastic and malignant categories. Although this aspect of the study suffers from low case numbers for supporting powerful statistical analysis as well as a selection bias because only cases with surgical follow-up were included in the analysis, it is reassuring that our institutional rates were within the ranges found in the literature. Also, any cases with benign diagnoses are usually not resected unless there is high clinical suspicion, and this adds to the potential for bias. With respect to the AUS category, the 3 malignant cases of the 9 total cases with surgical follow-up were diagnosed as lymphomas. When we excluded lymphomas from the analysis, the ROM in this category became 0%. These data fit with the previously described data from Rossi et al, 5 who found that all the false-positive cases in the study were initially diagnosed as either atypical or suspicious for a neoplasm, and the majority of false-negative cases were later diagnosed as lymphoma. It is often difficult for the most experienced cytopathologists to rule out a low-grade lymphoma solely on the basis of the cytomorphology of direct smears. 13, 14 In a study of 12,606 salivary gland FNA cases, Wang et al 15 reported an overall rate of 4% of atypical salivary gland cases. However, there was significant variability between institutions in the use of this category, with rates ranging from 0.7% to 17.0% of total FNA cases. Of these 504 cases, 154 had available histologic follow-up (30.6%) with an ROM of 61%. Of the 94 malignant cases with follow-up, 57 (61%) were lymphomas. The AUS frequency at our institution was 11% with surgical follow-up 60% of the time. Of the cases with histologic confirmation on surgical resection, 33% were malignant, and all were lymphomas (3 of 9 cases); this aligns with Wang et al's findings. Twenty-two percent of the AUS cases with surgical resection (2 of 9) were benign neoplasms (lipoma and pleomorphic adenoma), whereas 44% (4 of 9) were nonneoplastic. Despite the low numbers in our study, the trends are consistent with those published in the literature. An interesting data point within the study was the equal ROMs for the AUS and SUMP categories (33%). At our institution, with retrospective assignment of these categories to fit the MSRSGC, it is possible that the 2 categories have significant diagnostic overlap and, without adherence to strict definitions, may not discriminate between higher risk lesions. This represents an aspect of standardized reporting systems in which adequacy criteria are beneficial. In cases with adequate but low cellularity with some cellular or architectural atypia, pathologists would be able to use the atypical category with more confidence, and this would give more accuracy to each diagnostic category overall. Adequacy criteria also help to standardize nondiagnostic FNA rates across practice settings by giving all pathologists the same minimum cellularity from which an accurate diagnosis can feasibly be made.
Nondiagnostic FNA cases are subject to various technical factors, including operator experience, use of image guidance for small lesions, lesional heterogeneity, and any lesional cystic components. Eight of our 20 nondiagnostic FNA cases had histologic follow-up, with 6 cases showing neoplasms (3 malignant and 3 benign) on the final surgical pathology report. These false-negative cases may represent a sampling error. According to the proposed MSRSGC guidelines, the recommended management for nondiagnostic FNA cases should be clinical correlation and repeat sampling with image guidance. 16 One nondiagnostic FNA case in our study was managed with repeat FNA and was diagnosed as nonneoplastic.
IOR
In our study to assess the IOR of MSRSGC categories, we found fair and slight agreement for the AUS and SUMP categories, respectively. Observers preferentially used the AUS or benign neoplasm category for SUMP cases, perhaps because of unfamiliarity with the SUMP category as a diagnostic option. According to proposed guidelines, the AUS category is reserved for entities that do not reach either quantitative or qualitative cytomorphologic criteria to be diagnosed with confidence as either nonneoplastic or a benign neoplasm. Examples may include mucinous cyst contents only, oncocytic metaplasia versus a neoplasm, and reactive changes versus a neoplasm. On the other hand, the SUMP category is defined as diagnostic of a neoplasm, although the diagnosis of a specific entity cannot be made, and a malignant neoplasm cannot be ruled out. Examples of entities in the SUMP category may include a pleomorphic adenoma with atypia or metaplasia, myoepitheliomas, and basaloid neoplasms. This is a subtle distinction and requires the pathologist to commit to calling something neoplastic, whereas AUS does not. Our RON results confirm that AUS (RON, 56%) is less likely to result in a neoplastic lesion, whereas SUMP (RON, 100%) almost always denotes a neoplasm, although it may not predict for malignancy any better than AUS. IOR is greater in our study within the AUS category than the SUMP category. Fleiss' j for the category (0.217; P < .05) shows that although agreement within the category is higher than what can be attributed to random chance, the agreement is only fair. Within the SUMP category, reviewers preferentially used either the AUS or benign neoplasm category in place of SUMP. This could be due to unfamiliarity with the diagnostic category. Low IOR is not an uncommon finding within ambiguous diagnostic categories such as those observed in TBSRCC and TBSRTC. 8 that upon a second review of 3385 thyroid FNA cases sent to their institution for consultation, the diagnosis was changed in 32% of cases, and 8% of these cases involved 2-step differences in the 6-tier system, which can lead to significant changes in management. In summary, the proposed MSRSGC has the potential to standardize salivary gland FNA diagnoses, providing clear prognostic and management information to clinicians and surgeons. However, because of low IOR within less well-defined categories, pathologists must become familiar with the various scenarios that lead to an AUS or SUMP diagnosis. Defining and implementing adequacy criteria for salivary gland FNA cases may help in standardizing pathologist interpretations of samples. The initial adoption of a new reporting system will require a quality assessment to ensure that the system is reliable and useful for our clinical counterparts.
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